This announcement is a separate document:
武田薬品工業：武田薬品は、ドラベ症候群とレノックス・ガストー症候群の患者を対象としたソティクレスタット（TAK-935）の第3相トップライン結果を発表しました
Takeda Pharmaceutical: Takeda Pharmaceutical announced the Phase III topline results of Soticlestat (TAK-935) for patients with Dravet syndrome and Lennox-Gastaut syndrome.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.